Menu
Not yet recruiting NCT07438834

Continuous Sedation vs Daily Sedation Interruption in Ventilated Children

No phase Interventional Pneumonia Respiration Disorders

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Continuous Sedation Infusion (CSI), Daily Sedation Interruption (DSI).
Who it may be relevant to
Registry conditions: Pneumonia, Respiration Disorders. Basic parameters: 5 years — 10 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparison of Comfort Scores Between Continuous Midazolam Infusion and Daily Sedation Interruption in Mechanically Ventilated Pediatric Patients With Pneumonia: A Randomized Controlled Trial

Overview

Sedation is essential for mechanically ventilated pediatric patients to ensure comfort, ventilator synchrony, and prevention of self-extubation. However, excessive sedation may prolong mechanical ventilation and ICU stay, while inadequate sedation may cause agitation and physiological distress. Continuous Sedation Infusion (CSI) and Daily Sedation Interruption (DSI) are two commonly used strategies. Limited data exist comparing their impact on comfort levels in pediatric patients. This randomized controlled trial aims to compare comfort scores between continuous Midazolam infusion and daily sedation interruption in mechanically ventilated children aged 5-10 years diagnosed with pneumonia. Comfort will be assessed using the COMFORT-B Scale and Richmond Agitation-Sedation Scale (RASS) every 6 hours for 72 hours. The study intends to determine which strategy better maintains optimal sedation and comfort in pediatric intensive care settings.

Interventions

  • Other Continuous Sedation Infusion (CSI)
    Participants receive continuous intravenous Midazolam infusion titrated according to COMFORT-B and RASS scores following PICU sedation protocol.
  • Other Daily Sedation Interruption (DSI)
    Participants receive Midazolam infusion with daily interruption for 1-2 hours to assess neurological function and comfort level. Sedation is restarted if needed and titrated according to scoring scales.

Primary outcome measures

  • Mean COMFORT-B Score [Time frame: Every 6 hours during the first 72 hours of mechanical ventilation.]

Eligibility criteria

Inclusion criteria

Diagnosed with pneumonia

Requiring mechanical ventilation for at least 48 hours

Requiring sedation with intravenous Midazolam

Written informed consent obtained from parent or legal guardian

Exclusion criteria

Pre-existing neurological impairment (e.g., traumatic brain injury, stroke, cerebral palsy) that may interfere with comfort assessment

Presence of central nervous system symptoms affecting sedation evaluation

Contraindication to Midazolam (e.g., hypersensitivity, severe hypotension, significant hepatic dysfunction)

Receiving multiple sedative agents in addition to Midazolam

Refusal of parental or guardian consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07438834 · Exp135

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗